# Phibro Animal Health Corporation (PAHC) Q4 2025 Financial Results Summary
Phibro Animal Health Corporation (Nasdaq: PAHC) announced its financial results for the fourth quarter and fiscal year ended June 30, 2025, on August 27, 2025.
## Key Financial Highlights for Q4 2025
– **Net Sales**:
– $378.7 million, an increase of **$105.5 million**, or **39%** compared to Q4 2024.
– **Net Income**:
– $17.2 million, an increase of **$16.5 million** compared to $0.8 million in Q4 2024.
– **Diluted Earnings Per Share (EPS)**:
– $0.42, an increase of **$0.40** from $0.02 in Q4 2024.
– **Adjusted EBITDA**:
– $50.0 million, an increase of **$16.5 million**, or **49%** compared to Q4 2024.
– **Adjusted Net Income**:
– $23.2 million, an increase of **$6.6 million**, or **39%** compared to Q4 2024.
– **Adjusted Diluted EPS**:
– $0.57, up by **$0.16**, or **39%** from $0.41 in Q4 2024.
### Segment Performance for Q4 2025
– **Animal Health Sales**:
– $292.5 million, up **$101.0 million**, or **53%**.
– **Mineral Nutrition Sales**:
– $64.2 million, an increase of **$2.1 million**, or **3%**.
– **Performance Products Sales**:
– $22.1 million, up **$2.5 million**, or **13%**.
### Gross Profit
– **Gross Profit**:
– $110.0 million, up **$22.9 million**, or **26%**.
– **Gross Margin**:
– Decreased **290 basis points** to **29.0%** compared to **31.9%** in Q4 2024.
## Key Financial Highlights for FY 2025
– **Net Sales**:
– $1,296.2 million, an increase of **$278.5 million**, or **27%** from FY 2024.
– **Net Income**:
– $48.3 million, an increase of **$45.8 million** compared to $2.4 million in FY 2024.
– **Diluted EPS**:
– $1.19, an increase of **$1.13** from $0.06 in FY 2024.
– **Adjusted EBITDA**:
– $183.7 million, an increase of **$72.4 million**, or **65%** from FY 2024.
– **Adjusted Net Income**:
– $84.9 million, increasing by **$36.6 million**, or **76%** from FY 2024.
– **Adjusted Diluted EPS**:
– $2.09, up **$0.90**, or **76%** compared to $1.19 in FY 2024.
## Cash Flow and Balance Sheet
– **Free Cash Flow for FY 2025**:
– $41.8 million.
– **Total Debt**:
– $725.1 million with a leverage ratio of **3.1x** as of June 30, 2025.
– **Cash and Short-term Investments**:
– $77.0 million as of June 30, 2025.
## 2026 Financial Guidance
For the fiscal year ending June 30, 2026:
– **Net Sales**: Expected to be between $1.43 billion to $1.48 billion, representing **12%** growth.
– **Net Income**: Projected at $73 million to $83 million, a growth of **63%**.
– **Diluted EPS**: Expected between $1.79 and $2.03, representing **61%** growth.
– **Adjusted EBITDA**: Expected between $225 million to $235 million, reflecting **25%** growth.
– **Adjusted Net Income**: Anticipated at $103 million to $110 million, also indicating **25%** growth.
– **Adjusted Diluted EPS**: Forecasted between $2.52 to $2.70, representing **25%** growth.
### Dividend and Share Repurchase
– The report does not indicate any quarterly dividend declaration or share repurchase actions.
In conclusion, Phibro Animal Health Corporation’s financial results for Q4 and FY 2025 showcase a robust growth trajectory across various metrics, underscored by significant increases in sales, net income, and EBITDA. The company is also optimistic about sustained growth in FY 2026, aiming for significant year-over-year improvements.
Here are the extracted tables in HTML format:
### Condensed Consolidated Statements of Income (in millions)
| For the Periods Ended June 30 | 2025 | 2024 | Change | 2025 | 2024 | Change |
|---|---|---|---|---|---|---|
| Net sales | $378.7 | $273.2 | $105.5 39% | $1,296.2 | $1,017.7 | $278.5 27% |
| Cost of goods sold | $268.7 | $186.0 | $82.7 44% | $896.3 | $704.6 | $191.7 27% |
| Gross profit | $110.0 | $87.2 | $22.9 26% | $399.9 | $313.1 | $86.8 28% |
| Selling, general and administrative | $76.3 | $68.7 | $7.6 11% | $289.5 | $259.8 | $29.7 11% |
| Operating income | $33.7 | $18.4 | $15.3 83% | $110.5 | $53.3 | $57.1 * |
| Interest expense, net | $8.6 | $4.7 | $3.9 82% | $34.6 | $18.5 | $16.1 87% |
| Foreign currency losses, net | $1.3 | $7.3 | -$6.0 * | $7.9 | $23.9 | -$16.0 * |
| Income before income taxes | $23.8 | $6.4 | $17.4 * | $68.0 | $10.9 | $57.1 * |
| Provision for income taxes | $6.6 | $5.7 | $1.0 17% | $19.7 | $8.5 | $11.2 * |
| Net income | $17.2 | $0.8 | $16.5 * | $48.3 | $2.4 | $45.8 * |
| Net income per share – basic | $0.42 | $0.02 | $0.40 * | $1.19 | $0.06 | $1.13 * |
| diluted | $0.42 | $0.02 | $0.40 * | $1.19 | $0.06 | $1.13 * |
| Weighted average common shares outstanding – basic | 40.5 | 40.5 | ||||
| diluted | 40.7 | 40.6 | 40.7 | 40.5 |
### Condensed Consolidated Balance Sheets
| June 30, 2025 | June 30, 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $77.0 | $xx |
| Accounts receivable | $xx | $xx |
| Inventory | $xx | $xx |
| Other current assets | $xx | $xx |
| Total current assets | $xx | $xx |
| Property, plant, and equipment | $xx | $xx |
| Other long-term assets | $xx | $xx |
| Total assets | $xx | $xx |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities | $xx | $xx |
| Long-term debt | $725.1 million | $xx |
| Other long-term liabilities | $xx | $xx |
| Total liabilities | $xx | $xx |
| Stockholders’ equity | $xx | $xx |
| Total liabilities and stockholders’ equity | $xx | $xx |
(Note: The balance sheet table uses placeholders where specific values were not found; these should be filled with the relevant figures from the original press release, if available.)
